Definium Therapeutics (DFTX) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Definium Therapeutics (NASDAQ: DFTX):

• 7/18/2026 – Definium Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/17/2026 – Definium Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/8/2026 – Definium Therapeutics had its price target raised by Stifel Nicolaus from $30.00 to $60.00. They now have a “buy” rating on the stock.
• 7/4/2026 – Definium Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/30/2026 – Definium Therapeutics was given a new $58.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 6/24/2026 – Definium Therapeutics had its price target raised by JonesTrading from $61.00 to $74.00. They now have a “buy” rating on the stock.
• 6/23/2026 – Definium Therapeutics had its price target raised by Robert W. Baird from $37.00 to $57.00. They now have an “outperform” rating on the stock.
• 6/23/2026 – Definium Therapeutics had its price target raised by Needham & Company LLC from $38.00 to $50.00. They now have a “buy” rating on the stock.
• 6/22/2026 – Definium Therapeutics had its “buy” rating reaffirmed by Citigroup Inc..
• 6/22/2026 – Definium Therapeutics was given a new $60.00 price target by Canaccord Genuity Group Inc..
• 6/22/2026 – Definium Therapeutics was given a new $60.00 price target by Oppenheimer Holdings, Inc.. They now have an “outperform” rating on the stock.
• 6/22/2026 – Definium Therapeutics had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 6/22/2026 – Definium Therapeutics was given a new $52.00 price target by Leerink Partners. They now have an “outperform” rating on the stock.
• 6/16/2026 – Definium Therapeutics had its “buy” rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $38.00 price target on the stock.

Insider Transactions at Definium Therapeutics

In related news, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $135,675.39. Following the completion of the sale, the chief financial officer owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. This trade represents a 1.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Matthew T. Wiley sold 2,867 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the sale, the insider directly owned 174,633 shares of the company’s stock, valued at $7,863,723.99. The trade was a 1.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 48,096 shares of company stock worth $2,165,763 in the last three months. Insiders own 2.40% of the company’s stock.

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.